Clinical data
| Placebo (n=4)† | CCR1 antagonist (n=12)† | |||||
|---|---|---|---|---|---|---|
| Measure of activity | Before mean (SEM) | After mean (SEM) | p Value‡ | Before mean (SEM) | After mean (SEM) | p Value‡ |
| *VAS denotes visual analogue scale, 0 is best and 100 is worst; **HAQ denotes Health Assessment Questionnaire, on this scale 0 is best and 3 is worst; ***on this scale 1 is best and 5 is worst. | ||||||
| †For patients who received intra-articular corticosteroids on day 15 (n=4), the clinical data of day 15 (before corticosteroids) were used instead of the day 18 data. | ||||||
| ‡The paired t test was used to determine significant differences within each treatment group. There were no statistical differences in change between the placebo group and the CCR1 antagonist group. | ||||||
| Tender joint count | 10 (3) | 7 (2) | NS | 17 (3) | 12 (3) | 0.021 |
| Swollen joint count | 13 (2) | 10 (2) | NS | 19 (1) | 14 (2) | 0.001 |
| Pain (VAS*) | 8 (2) | 12 (3) | NS | 17 (2) | 13 (3) | NS |
| ESR (mm/1st h) | 26 (11) | 31 (12) | 0.045 | 19 (3) | 22 (4) | 0.037 |
| Quality of life (HAQ**) | 1.313 (0.514) | 1.219 (0.434) | NS | 1.500 (0.210) | 1.250 (0.205) | 0.037 |
| Patient assessment of disease activity*** | 3 (0) | 3 (0) | NS | 3 (0) | 3 (0) | NS |
| Doctor assessment of disease activity*** | 3 (0) | 3 (0) | NS | 3 (0) | 3 (0) | NS |
| Disease activity score (DAS) | 4.69 (0.54) | 4.60 (0.47) | NS | 5.58 (0.26) | 4.87 (0.39) | 0.012 |
| Subjects responding to ACR20 criteria | 0 | 4 | ||||